Literature DB >> 15246322

Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets.

Aditi Das1, Arindam Dasgupta, Tanushri Sengupta, Hemanta K Majumder.   

Abstract

The protozoan parasites Trypanosoma, Leishmania and Crithidia, which belong to the order kinetoplastidae, emerge from the most ancient eukaryotic lineages. The diversity found in the life cycle of these organisms must be directed by genetic events, wherein topoisomerases play an important role in cellular processes affecting the topology and organization of intracellular DNA. Topoisomerases are valuable as potential drug targets because they have indispensable function in cell biology. This review summarizes what is known about topoisomerase genes and proteins of kinetoplastid parasites and the roles of these enzymes as targets for therapeutic agents.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15246322     DOI： 10.1016/j.pt.2004.06.005

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN： 1471-4922


  14 in total

Review 1.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

2.  Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide.

Authors:  Tanushri Sengupta; Mandira Mukherjee; Aditi Das; Chhabinath Mandal; Rakhee Das; Tanmoy Mukherjee; Hemanta K Majumder
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

3.  Drug targets in Leishmania.

Authors:  Bhavna Chawla; Rentala Madhubala
Journal:  J Parasit Dis       Date:  2010-10-08

4.  Activity of indenoisoquinolines against African trypanosomes.

Authors:  Rahul P Bakshi; Dongpei Sang; Andrew Morrell; Mark Cushman; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

5.  A Novel Spirooxindole Derivative Inhibits the Growth of Leishmania donovani Parasites both In Vitro and In Vivo by Targeting Type IB Topoisomerase.

Authors:  Sourav Saha; Chiranjit Acharya; Uttam Pal; Somenath Roy Chowdhury; Kahini Sarkar; Nakul C Maiti; Parasuraman Jaisankar; Hemanta K Majumder
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  Development of derivatives of 3, 3'-diindolylmethane as potent Leishmania donovani bi-subunit topoisomerase IB poisons.

Authors:  Amit Roy; Sayan Chowdhury; Souvik Sengupta; Madhumita Mandal; Parasuraman Jaisankar; Ilda D'Annessa; Alessandro Desideri; Hemanta K Majumder
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

7.  Repetitive DNA is associated with centromeric domains in Trypanosoma brucei but not Trypanosoma cruzi.

Authors:  Samson O Obado; Christopher Bot; Daniel Nilsson; Bjorn Andersson; John M Kelly
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

8.  Characterization of the DNA-binding domain and identification of the active site residue in the 'Gyr A' half of Leishmania donovani topoisomerase II.

Authors:  Tanushri Sengupta; Mandira Mukherjee; Rakhee Das; Aditi Das; Hemanta K Majumder
Journal:  Nucleic Acids Res       Date:  2005-04-28       Impact factor: 16.971

9.  Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.

Authors:  Benu Brata Das; Nilkantha Sen; Amit Roy; Somdeb Bose Dasgupta; Agneyo Ganguly; Bikash Chandra Mohanta; Biswanath Dinda; Hemanta K Majumder
Journal:  Nucleic Acids Res       Date:  2006-02-18       Impact factor: 16.971

10.  Deletion study of DNA topoisomerase IB from Leishmania donovani: searching for a minimal functional heterodimer.

Authors:  Rosario Díaz González; Yolanda Pérez Pertejo; David Ordóñez; Rafael Balaña-Fouce; Rosa M Reguera
Journal:  PLoS One       Date:  2007-11-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.